Current Report Filing (8-k)
July 14 2016 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 14,
2016
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-36457
|
|
90-0031917
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)
(866) 594-5999
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On July 13, 2016, Provectus Biopharmaceuticals, Inc. (the
Company) suspended sales of its common stock under the Controlled Equity Offering Sales Agreement, dated as of April 30, 2014, by and between the Company and Cantor Fitzgerald & Co. The Company expects the suspension to
last until December 31, 2016, but no assurances can be given that the Company will not extend the suspension beyond that date. The Company also has the ability to lift the suspension prior to December 31, 2016, should it desire to make
sales of its common stock under the Controlled Equity Offering Sales Agreement prior to December 31, 2016.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: July 14, 2016
|
|
|
PROVECTUS BIOPHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Peter R. Culpepper
|
|
|
Peter R. Culpepper
|
|
|
Interim Chief Executive Officer and Chief Operating Officer
|
2
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024